AU2020235263B2 - Antibodies targeting C5aR - Google Patents
Antibodies targeting C5aRInfo
- Publication number
- AU2020235263B2 AU2020235263B2 AU2020235263A AU2020235263A AU2020235263B2 AU 2020235263 B2 AU2020235263 B2 AU 2020235263B2 AU 2020235263 A AU2020235263 A AU 2020235263A AU 2020235263 A AU2020235263 A AU 2020235263A AU 2020235263 B2 AU2020235263 B2 AU 2020235263B2
- Authority
- AU
- Australia
- Prior art keywords
- seq
- antibody
- human
- region
- c5ar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19162759 | 2019-03-14 | ||
| EP19162759.5 | 2019-03-14 | ||
| PCT/EP2020/056754 WO2020182974A1 (en) | 2019-03-14 | 2020-03-13 | Antibodies targeting c5ar |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2020235263A1 AU2020235263A1 (en) | 2021-09-02 |
| AU2020235263B2 true AU2020235263B2 (en) | 2026-06-04 |
Family
ID=65812165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020235263A Active AU2020235263B2 (en) | 2019-03-14 | 2020-03-13 | Antibodies targeting C5aR |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20220135658A1 (enExample) |
| EP (1) | EP3938393A1 (enExample) |
| JP (2) | JP7617012B2 (enExample) |
| KR (1) | KR102977518B1 (enExample) |
| CN (1) | CN113574072B (enExample) |
| AU (1) | AU2020235263B2 (enExample) |
| BR (1) | BR112021017860A2 (enExample) |
| CA (1) | CA3132771A1 (enExample) |
| IL (1) | IL286238A (enExample) |
| MA (1) | MA55285A (enExample) |
| MX (1) | MX2021011040A (enExample) |
| SG (1) | SG11202108761YA (enExample) |
| TW (1) | TWI901581B (enExample) |
| WO (1) | WO2020182974A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| WO2022057910A1 (en) * | 2020-09-17 | 2022-03-24 | I-Mab Biopharma Co., Ltd | Combination therapies targeting c5ar and pd-1/pd-l1 pathways |
| US11912781B2 (en) * | 2021-01-13 | 2024-02-27 | Visterra, Inc. | Humanized complement 5A receptor 1 antibodies and methods of use thereof |
| WO2024236163A1 (en) | 2023-05-17 | 2024-11-21 | Morphosys Ag | T cell receptor beta constant region 2 (trbc2) antibodies |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012168199A1 (en) * | 2011-06-06 | 2012-12-13 | Novo Nordisk A/S | Therapeutic antibodies |
| WO2018234118A1 (en) * | 2017-06-23 | 2018-12-27 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
| CA2347973C (en) | 1999-07-20 | 2010-06-22 | Morphosys Ag | Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
| US8071096B2 (en) * | 2002-01-25 | 2011-12-06 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| KR101559599B1 (ko) * | 2007-11-26 | 2015-10-12 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 항-메소텔린 항체 및 이의 용도 |
| CA2714296A1 (en) * | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | Humanized anti-c5ar antibodies |
| AU2011245117B2 (en) * | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| DK2994488T3 (da) * | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| ES2736500T3 (es) | 2014-06-18 | 2020-01-02 | Morphosys Ag | Proteínas de fusión y usos de las mismas |
-
2020
- 2020-03-13 US US17/434,249 patent/US20220135658A1/en not_active Abandoned
- 2020-03-13 MX MX2021011040A patent/MX2021011040A/es unknown
- 2020-03-13 KR KR1020217032794A patent/KR102977518B1/ko active Active
- 2020-03-13 AU AU2020235263A patent/AU2020235263B2/en active Active
- 2020-03-13 BR BR112021017860A patent/BR112021017860A2/pt unknown
- 2020-03-13 SG SG11202108761YA patent/SG11202108761YA/en unknown
- 2020-03-13 EP EP20710933.1A patent/EP3938393A1/en active Pending
- 2020-03-13 MA MA055285A patent/MA55285A/fr unknown
- 2020-03-13 WO PCT/EP2020/056754 patent/WO2020182974A1/en not_active Ceased
- 2020-03-13 CN CN202080021131.1A patent/CN113574072B/zh active Active
- 2020-03-13 JP JP2021554761A patent/JP7617012B2/ja active Active
- 2020-03-13 TW TW109108367A patent/TWI901581B/zh active
- 2020-03-13 CA CA3132771A patent/CA3132771A1/en active Pending
-
2021
- 2021-09-09 IL IL286238A patent/IL286238A/en unknown
-
2023
- 2023-08-25 US US18/456,323 patent/US12018072B2/en active Active
-
2024
- 2024-05-08 US US18/658,860 patent/US20240400657A1/en active Pending
-
2025
- 2025-01-06 JP JP2025001775A patent/JP7842914B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012168199A1 (en) * | 2011-06-06 | 2012-12-13 | Novo Nordisk A/S | Therapeutic antibodies |
| WO2018234118A1 (en) * | 2017-06-23 | 2018-12-27 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of c5a activity |
Also Published As
| Publication number | Publication date |
|---|---|
| US12018072B2 (en) | 2024-06-25 |
| JP2025069140A (ja) | 2025-04-30 |
| JP7842914B2 (ja) | 2026-04-08 |
| WO2020182974A1 (en) | 2020-09-17 |
| EP3938393A1 (en) | 2022-01-19 |
| US20220135658A1 (en) | 2022-05-05 |
| TW202041535A (zh) | 2020-11-16 |
| MA55285A (fr) | 2022-01-19 |
| US20240400657A1 (en) | 2024-12-05 |
| AU2020235263A1 (en) | 2021-09-02 |
| TWI901581B (zh) | 2025-10-21 |
| JP7617012B2 (ja) | 2025-01-17 |
| SG11202108761YA (en) | 2021-09-29 |
| BR112021017860A2 (pt) | 2021-12-07 |
| KR102977518B1 (ko) | 2026-06-12 |
| KR20210141988A (ko) | 2021-11-23 |
| US20240018225A1 (en) | 2024-01-18 |
| MX2021011040A (es) | 2021-12-10 |
| NZ778810A (en) | 2025-10-31 |
| JP2022524449A (ja) | 2022-05-02 |
| CN113574072A (zh) | 2021-10-29 |
| CN113574072B (zh) | 2023-12-12 |
| IL286238A (en) | 2021-10-31 |
| CA3132771A1 (en) | 2020-09-17 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO MORPHOSYS GMBH |